Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director | May 04, 2020 | May 05, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date May 04, 2020 · Filed May 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,860 |
Ending reported balance
After 2020-05-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-05-04 · Exercise / conversion · Acquired 2,416 · Balance 57,276 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Row 2 · 2020-05-04 · Sale · Disposed 2,416 · Balance 54,860 |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.63 · Expires 2020-05-11 | Direct | 0 |
Reported balance
After 2020-05-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-04 · Exercise / conversion · Disposed 2,416 · Balance 0 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2: The options vested quarterly over the first year of service and were fully vested on May 11, 2011. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
F2: The options vested quarterly over the first year of service and were fully vested on May 11, 2011.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 20, 2019 Filed Mar 21, 2019 23:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,700 | $22.02 | $59,440.50 |
DisclosureSEC source: 0001127602-19-012726 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 09, 2018 Filed May 11, 2018 23:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 2,283 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-017239 · form4.xml · derivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,283 Underlying: Common Stock · 2,283 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 9, 2019, or the day immediately preceding the next regular annual stockholders meeting. F3 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 9, 2019, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 09, 2018 Filed May 11, 2018 23:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 9,496 | $0.00 Strike: $65.69 | $0.00 |
DisclosureSEC source: 0001127602-18-017239 · form4.xml · derivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,496 Underlying: Common Stock · 9,496 shares Expires 2028-05-09 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary measured from May 9, 2018 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 9, 2019 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 08, 2018 Filed May 10, 2018 20:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,241 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-016976 · form4.xml · derivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,241 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 8, 2018. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 8, 2018. Read SEC document |
| May 08, 2018 Filed May 10, 2018 20:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,241 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-016976 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 04, 2018 Filed May 8, 2018 17:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 5,836 | $0.00 Strike: $26.62 | $0.00 |
DisclosureSEC source: 0001127602-18-016577 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,836 shares Expires 2018-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Options vest quarterly over a period of one year from date of grant. Read SEC document |
| May 04, 2018 Filed May 8, 2018 17:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,836 | $65.09 | $379,885.08 |
DisclosureSEC source: 0001127602-18-016577 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,619 F2 · price: Sale prices reported for the transactions reported here range from $64.72 to $65.42. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 04, 2018 Filed May 8, 2018 17:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,836 | $26.62 | $155,325.14 |
DisclosureSEC source: 0001127602-18-016577 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 27, 2018 Filed Apr 30, 2018 21:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 5,833 | $0.00 Strike: $26.62 | $0.00 |
DisclosureSEC source: 0001127602-18-015606 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,836 Underlying: Common Stock · 5,833 shares Expires 2018-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options vest quarterly over a period of one year from date of grant. Read SEC document |
| April 27, 2018 Filed Apr 30, 2018 21:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,833 | $73.91 | $431,117.03 |
DisclosureSEC source: 0001127602-18-015606 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,619 Read SEC document |
| April 27, 2018 Filed Apr 30, 2018 21:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,833 | $26.62 | $155,245.30 |
DisclosureSEC source: 0001127602-18-015606 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 20, 2018 Filed Apr 23, 2018 23:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 5,833 | $0.00 Strike: $26.62 | $0.00 |
DisclosureSEC source: 0001127602-18-015126 · form4.xml · derivative · entry 4 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,669 Underlying: Common Stock · 5,833 shares Expires 2018-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: Options vest quarterly over a period of one year from date of grant. Read SEC document |
| April 20, 2018 Filed Apr 23, 2018 23:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,333 | $73.77 | $393,434.61 |
DisclosureSEC source: 0001127602-18-015126 · form4.xml · nonDerivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,619 F3 · price: Sale prices reported for the transactions reported here range from $73.45 to $74.40. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| April 20, 2018 Filed Apr 23, 2018 23:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $73.39 | $36,695.50 |
DisclosureSEC source: 0001127602-18-015126 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,952 F2 · price: Sale prices reported for the transactions reported here range from $73.33 to $73.44. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| April 20, 2018 Filed Apr 23, 2018 23:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,833 | $26.62 | $155,245.30 |
DisclosureSEC source: 0001127602-18-015126 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 13, 2018 Filed Apr 16, 2018 22:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 5,833 | $0.00 Strike: $26.62 | $0.00 |
DisclosureSEC source: 0001127602-18-014687 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,502 Underlying: Common Stock · 5,833 shares Expires 2018-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options vest quarterly over a period of one year from date of grant. Read SEC document |
| April 13, 2018 Filed Apr 16, 2018 22:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,833 | $75.56 | $440,741.48 |
DisclosureSEC source: 0001127602-18-014687 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,619 Read SEC document |
| April 13, 2018 Filed Apr 16, 2018 22:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,833 | $26.62 | $155,245.30 |
DisclosureSEC source: 0001127602-18-014687 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 06, 2018 Filed Apr 9, 2018 22:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 5,833 | $0.00 Strike: $26.62 | $0.00 |
DisclosureSEC source: 0001127602-18-014291 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,335 Underlying: Common Stock · 5,833 shares Expires 2018-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options vest quarterly over a period of one year from date of grant. Read SEC document |
| April 06, 2018 Filed Apr 9, 2018 22:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,833 | $74.47 | $434,383.51 |
DisclosureSEC source: 0001127602-18-014291 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,619 Read SEC document |
| April 06, 2018 Filed Apr 9, 2018 22:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,833 | $26.62 | $155,245.30 |
DisclosureSEC source: 0001127602-18-014291 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 5,833 | $0.00 Strike: $26.62 | $0.00 |
DisclosureSEC source: 0001127602-18-014028 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,168 Underlying: Common Stock · 5,833 shares Expires 2018-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options vest quarterly over a period of one year from date of grant. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,833 | $74.93 | $437,066.69 |
DisclosureSEC source: 0001127602-18-014028 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,619 Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,833 | $26.62 | $155,245.30 |
DisclosureSEC source: 0001127602-18-014028 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 23, 2018 Filed Mar 26, 2018 22:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 5,833 | $0.00 Strike: $26.62 | $0.00 |
DisclosureSEC source: 0001127602-18-012796 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,001 Underlying: Common Stock · 5,833 shares Expires 2018-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Options vest quarterly over a period of one year from date of grant. Read SEC document |
| March 23, 2018 Filed Mar 26, 2018 22:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,833 | $75.02 | $437,587.58 |
DisclosureSEC source: 0001127602-18-012796 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,619 F2 · price: Sale prices reported for the transactions reported here range from $74.63 to $75.41. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| March 23, 2018 Filed Mar 26, 2018 22:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,833 | $26.62 | $155,245.30 |
DisclosureSEC source: 0001127602-18-012796 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 16, 2018 Filed Mar 20, 2018 17:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 5,833 | $0.00 Strike: $26.62 | $0.00 |
DisclosureSEC source: 0001127602-18-012214 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,834 Underlying: Common Stock · 5,833 shares Expires 2018-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Options vest quarterly over a period of one year from date of grant. Read SEC document |
| March 16, 2018 Filed Mar 20, 2018 17:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,833 | $80.09 | $467,137.55 |
DisclosureSEC source: 0001127602-18-012214 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,619 F2 · price: Sale prices reported for the transactions reported here range from $79.92 to $80.80. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| March 16, 2018 Filed Mar 20, 2018 17:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,833 | $26.62 | $155,245.30 |
DisclosureSEC source: 0001127602-18-012214 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 20:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 5,833 | $0.00 Strike: $26.62 | $0.00 |
DisclosureSEC source: 0001127602-18-011383 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,667 Underlying: Common Stock · 5,833 shares Expires 2018-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options vest quarterly over a period of one year from date of grant. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 20:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,833 | $80.93 | $472,064.69 |
DisclosureSEC source: 0001127602-18-011383 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,619 Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 20:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,833 | $26.62 | $155,245.30 |
DisclosureSEC source: 0001127602-18-011383 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 10, 2017 Filed May 12, 2017 22:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 2,241 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-018005 · form4.xml · derivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,241 Underlying: Common Stock · 2,241 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 9, 2018, or the day immediately preceding the next regular annual stockholders meeting. F3 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 9, 2018, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 10, 2017 Filed May 12, 2017 22:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 10,376 | $0.00 Strike: $66.92 | $0.00 |
DisclosureSEC source: 0001127602-17-018005 · form4.xml · derivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,376 Underlying: Common Stock · 10,376 shares Expires 2027-05-10 F1 · derivative.exercise_date: Options vest quarterly over the first year of service upon the earlier of May 9, 2018, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 09, 2017 Filed May 11, 2017 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $20.71 | $0.00 |
DisclosureSEC source: 0001127602-17-017792 · form4.xml · derivative · entry 5 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2017-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| May 09, 2017 Filed May 11, 2017 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,787 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-017792 · form4.xml · derivative · entry 4 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,787 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 9, 2017. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 9, 2017. Read SEC document |
| May 09, 2017 Filed May 11, 2017 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 9,943 | $67.25 | $668,666.75 |
DisclosureSEC source: 0001127602-17-017792 · form4.xml · nonDerivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,619 F3 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 09, 2017 Filed May 11, 2017 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 15,000 | $20.71 | $310,575.00 |
DisclosureSEC source: 0001127602-17-017792 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 09, 2017 Filed May 11, 2017 22:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,787 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-017792 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 11, 2016 Filed May 13, 2016 23:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 7,321 | $0.00 Strike: $83.90 | $0.00 |
DisclosureSEC source: 0001127602-16-052229 · form4.xml · derivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,321 Underlying: Common Stock · 7,321 shares Expires 2026-05-11 F3 · derivative.exercise_date: Options vest quarterly over the first year of service upon the earlier of May 11, 2017, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 11, 2016 Filed May 13, 2016 23:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 1,787 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-16-052229 · form4.xml · derivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,787 Underlying: Common Stock · 1,787 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 11, 2017, or the day immediately preceding the next regular annual stockholders meeting. F2 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 11, 2017, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2016 Filed May 10, 2016 20:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-16-051682 · form4.xml · derivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,466 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 6, 2016. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 6, 2016. Read SEC document |
| May 06, 2016 Filed May 10, 2016 20:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-16-051682 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| November 24, 2015 Filed Nov 25, 2015 19:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $20.71 | $0.00 |
DisclosureSEC source: 0001179110-15-015444 · edgar.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2017-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| November 24, 2015 Filed Nov 25, 2015 19:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 15,000 | $105.95 | $1,589,190.00 |
DisclosureSEC source: 0001179110-15-015444 · edgar.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,309 F3 · price: Sale prices reported for the transactions reported here range from $105.51 to $106.28. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 24, 2015 Filed Nov 25, 2015 19:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 15,000 | $20.71 | $310,575.00 |
DisclosureSEC source: 0001179110-15-015444 · edgar.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 27, 2015 Filed Oct 29, 2015 00:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $20.71 | $0.00 |
DisclosureSEC source: 0001179110-15-014265 · edgar.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 15,000 shares Expires 2017-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| October 27, 2015 Filed Oct 29, 2015 00:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 15,000 | $110.00 | $1,650,000.00 |
DisclosureSEC source: 0001179110-15-014265 · edgar.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,309 Read SEC document |
| October 27, 2015 Filed Oct 29, 2015 00:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 15,000 | $20.71 | $310,575.00 |
DisclosureSEC source: 0001179110-15-014265 · edgar.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.